Bionomics to Participate in William Blair’s Biotech Focus Conference 2022

Rhea-AI Summary

Bionomics Limited (Nasdaq: BNOX | ASX: BNO) announced that Dr. Errol De Souza, Executive Chairman, will participate in a panel on "Unmet Needs and Novel Therapies in Neuropsychiatry" at the William Blair Biotech Focus Conference on July 13, 2022, at 9:00 am ET. He will also conduct one-on-one meetings with investors. Bionomics is focused on developing allosteric ion channel modulators to address serious CNS disorders. Their lead drug, BNC210, targets Social Anxiety Disorder and PTSD. For more information, visit Bionomics' website.

ADELAIDE, Australia, July 08, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that Dr. Errol De Souza, Executive Chairman of Bionomics, will participate in a panel on “Unmet Needs and Novel Therapies in Neuropsychiatry” at the William Blair Biotech Focus Conference taking place virtually and in-person in New York on July 12-13, 2022.

The “Unmet Needs and Novel Therapies in Neuropsychiatry” panel will take place on Wednesday, July 13^th at 9:00am ET.

In addition to participating in the panel, Dr. De Souza will host one-on-one meetings with investors at the conference. An audio webcast link for the event, when available, will be posted to Bionomics’ website found on the ‘Events & Presentations’ page within the ‘Investor Center’ section.

FOR FURTHER INFORMATION PLEASE CONTACT:

Investor Relations Mr. Connor Bernstein Vice President, Strategy and Corporate Development +1 (650) 524-5143 cbernstein@bionomics.com.au

Investor Relations Kevin Gardner kgardner@lifesciadvisors.com

About Bionomics Limited
Bionomics (ASX:BNO, NASDAQ:BNOX) is a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious CNS disorders with high unmet medical need. Bionomics is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute treatment of Social Anxiety Disorder (SAD) and chronic treatment of Post-Traumatic Stress Disorder (PTSD). Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer’s disease and other central nervous system conditions.

www.bionomics.com.au

 

FAQ

What is the date and time of the Bionomics panel at the William Blair Biotech Focus Conference?

The Bionomics panel will take place on July 13, 2022, at 9:00 am ET.

Who will represent Bionomics at the William Blair Biotech Focus Conference?

Dr. Errol De Souza, Executive Chairman of Bionomics, will represent the company.

What is the focus of Bionomics’ lead drug candidate BNC210?

BNC210 is aimed at treating Social Anxiety Disorder and chronic Post-Traumatic Stress Disorder.

What type of company is Bionomics?

Bionomics is a clinical-stage biopharmaceutical company developing therapies for serious CNS disorders.

Where can I find more information about Bionomics and their events?

More information can be found on Bionomics' website under the 'Events & Presentations' section.